Medication

Results were presented from a phase 2b parallel group RCT of the dopamine D1 antagonist ecopipam in 153 children and adolescents with TS \citep{wanaski2022,36628546}. YGTSS total tic scores and clinician severity ratings both declined significantly more in the active treatment group, without adverse metabolic or motor effects (such as akathisia or rigidity-bradykinesia).